Resverlogix Converts $2.8 Million Interest into Equity in Insider-led Financing

Resverlogix ( (TSE:RVX) ) has shared an update.

Resverlogix Corp. has completed a CAD$2.8 million shares-for-interest private placement with an immediate family member of its Chairman and CEO, who subscribed for 28,000,000 common shares at CAD$0.10 each. Following the deal, the investor holds about 9.7% of the company’s outstanding common shares, which are subject to a four-month hold period.

The transaction effectively converts accrued interest on indebtedness, originally owed by Resverlogix to Zenith Capital Corp., into equity held by the related-party subscriber via an interest assignment. This move strengthens Resverlogix’s balance sheet by reducing interest-bearing liabilities while deepening insider ownership, a development that may signal confidence in the company’s long-term prospects to investors.

More about Resverlogix

Resverlogix Corp. is a Calgary-based late-stage biotechnology company specializing in epigenetics, with a focus on developing first-in-class therapies for chronic diseases. Its lead candidate, apabetalone, is being evaluated for the treatment of cardiovascular disease, related comorbidities, and post-COVID-19 conditions, and the company’s shares trade on the Toronto Stock Exchange under the symbol RVX.

Average Trading Volume: 39,718

Technical Sentiment Signal: Hold

Current Market Cap: C$27.33M

For an in-depth examination of RVX stock, go to TipRanks’ Overview page.